Simon Brazier has completed his overhaul of the £164m Investec UK Alpha fund, trimming positions in "expensive" cyclical stocks in favour of more globally diversified companies.
Brazier (pictured) officially took over the management of the fund on 12 January, after stepping down as head of UK equities at Threadneedle last September, and has now finished adjusting the fund to suit his investment style and outlook. He has initiated new positions in blue chip pharmas GlaxoSmithKline and AstraZeneca, added entertainment group Merlin, speciality chemicals company Johnson Matthey, and consumer goods company Reckitt Benckiser. He favours these stocks as they are "globally diversified, cash generative companies with attractive business models, strong financials, and ...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
